DE69434569D1 - Verfahren zur erhöhung der überlebensrate von neuronen und dafür verwendbare mittel - Google Patents

Verfahren zur erhöhung der überlebensrate von neuronen und dafür verwendbare mittel

Info

Publication number
DE69434569D1
DE69434569D1 DE69434569T DE69434569T DE69434569D1 DE 69434569 D1 DE69434569 D1 DE 69434569D1 DE 69434569 T DE69434569 T DE 69434569T DE 69434569 T DE69434569 T DE 69434569T DE 69434569 D1 DE69434569 D1 DE 69434569D1
Authority
DE
Germany
Prior art keywords
neurons
increasing
survival rate
medium use
medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69434569T
Other languages
English (en)
Other versions
DE69434569T2 (de
Inventor
Graham Leslie Barrett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Walter and Eliza Hall Institute of Medical Research
Original Assignee
Walter and Eliza Hall Institute of Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Walter and Eliza Hall Institute of Medical Research filed Critical Walter and Eliza Hall Institute of Medical Research
Application granted granted Critical
Publication of DE69434569D1 publication Critical patent/DE69434569D1/de
Publication of DE69434569T2 publication Critical patent/DE69434569T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
DE69434569T 1993-10-18 1994-10-18 Verfahren zur erhöhung der überlebensrate von neuronen und dafür verwendbare mittel Expired - Lifetime DE69434569T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPM187093 1993-10-18
AUPM187093 1993-10-18
PCT/AU1994/000631 WO1995011253A1 (en) 1993-10-18 1994-10-18 A method for enhancing neurone survival and agents useful for same

Publications (2)

Publication Number Publication Date
DE69434569D1 true DE69434569D1 (de) 2006-01-12
DE69434569T2 DE69434569T2 (de) 2006-08-24

Family

ID=3777280

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69434569T Expired - Lifetime DE69434569T2 (de) 1993-10-18 1994-10-18 Verfahren zur erhöhung der überlebensrate von neuronen und dafür verwendbare mittel

Country Status (7)

Country Link
US (2) US5837694A (de)
EP (2) EP1683863A3 (de)
JP (1) JP4281926B2 (de)
AT (1) ATE312175T1 (de)
CA (1) CA2174425A1 (de)
DE (1) DE69434569T2 (de)
WO (1) WO1995011253A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000067777A1 (en) * 1999-05-07 2000-11-16 Biofan Pty Ltd A method of prophylaxis and treatment and agents useful therefor
US8110217B2 (en) * 2001-08-13 2012-02-07 University Of Pittsburgh Sphingomyelin liposomes for the treatment of hyperactive bladder disorders
WO2003015698A2 (en) * 2001-08-13 2003-02-27 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
AUPS230702A0 (en) * 2002-05-14 2002-06-13 Walter And Eliza Hall Institute Of Medical Research, The A method of treatment
US20040176291A1 (en) * 2002-09-24 2004-09-09 Elly Nedivi Methods and compositions for soluble CPG15
JP2007528202A (ja) * 2003-03-28 2007-10-11 株式会社インテレクチャル・プロパティ・コンサルティング 神経再生のための組成物および方法
US7556942B2 (en) * 2003-07-15 2009-07-07 Board Of Regents, The University Of Texas System Tumor suppressor designated Hippo
BRPI0414222B8 (pt) 2003-09-09 2021-05-25 Geron Corp compostos oligonucleotídeos modificados para inibição da telomerase, métodos, composição farmacêutica e usos relacionados
WO2005032476A2 (en) * 2003-09-30 2005-04-14 Massachusetts Institute Of Technology Methods and compositions for cpg15-2
US7884078B2 (en) * 2006-02-10 2011-02-08 Massachusetts Institute Of Technology CPG15 compounds as insulin receptor and insulin-like growth factor receptor agonists
WO2008094640A2 (en) 2007-01-30 2008-08-07 Geron Corporation Compounds having anti-adhesive effects on cancer cells
JOP20200257A1 (ar) 2014-05-01 2017-06-16 Geron Corp تركيبات أوليجو نوكليوتيد وطرق لتحضيرها

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2006008C (en) * 1988-12-20 2000-02-15 Donald J. Kessler Method for making synthetic oligonucleotides which bind specifically to target sites on duplex dna molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5585479A (en) * 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA
CA2144421A1 (en) 1992-09-11 1994-03-31 Tadayoshi Nakamura Refined magnesium material and method for producing the same
CA2143945A1 (en) * 1992-09-11 1994-03-31 Daniel Djakiew A method for the detection and treatment of prostate disease

Also Published As

Publication number Publication date
EP0724589A4 (de) 1998-09-16
EP1683863A2 (de) 2006-07-26
DE69434569T2 (de) 2006-08-24
US5837694A (en) 1998-11-17
EP1683863A3 (de) 2006-08-02
CA2174425A1 (en) 1995-04-27
US6174869B1 (en) 2001-01-16
JPH09503512A (ja) 1997-04-08
EP0724589A1 (de) 1996-08-07
EP0724589B1 (de) 2005-12-07
ATE312175T1 (de) 2005-12-15
JP4281926B2 (ja) 2009-06-17
WO1995011253A1 (en) 1995-04-27

Similar Documents

Publication Publication Date Title
DE69434569D1 (de) Verfahren zur erhöhung der überlebensrate von neuronen und dafür verwendbare mittel
BR9206026A (pt) Análogo de oligonucleotídio, processo para modular a produção ou atividade de uma proteína em um organismo, e, processo para proteger um análogo de oligonucleotídio ou nucleosídio bifuncional
DE69126710T2 (de) Oligonukleotide zur modulation der effekte von cytomegalovirusinfektionen
DE69913665D1 (de) Verwendung von follistatin zur herstellung eines arzneimittels zur behandlung von muskuläre krankheiten
ATE289200T1 (de) Oligonucleotidzusammenstellung und verfahren zur regulierung der protein b7 expression
DE3886254D1 (de) Apparat zur Behandlung von biologischen Proben und Behandlungsmethoden mit dem Apparat.
ATE271874T1 (de) Verwendung von inosine zur herstellung eines medikamentes zur stimulierung des axonwachstums von zns-neuronen
DE309309T1 (de) Blattfoermiges material zur haut- oder haarbehandlung, verfahren zu dessen herstellung und aus diesem material hergestellte gegenstaende.
DE3888274D1 (de) Vorrichtung zur intensiven und kontrollierten Herstellung von Mikroorganismen durch Photosynthese.
DE69434209D1 (de) REGULATION DER GENEXPRESSION VON bcl-2
EP1123414A4 (de) Antisense modulation der expression von integrin alpha 4
HUT66458A (en) Oligonucleotide and rybozyme analogoues with terminal 3'-3' or 5'-5'bonds, and process for preparing pharmaceutical preparations containing them
ATE259652T1 (de) Neuronale verwendungen des bmp-11
DE3861352D1 (de) Hydrokrackverfahren von kohlenwasserstoffen und vorrichtung zur ausfuehrung des verfahrens.
DE69431199T2 (de) Melatonin-Derivate zur Verwendung in der Behandlung von Schlafstörungen
DE69432626D1 (de) Melatonin-Derivate zur Verwendung in der Behandlung von Desynchronisierungs-Erkankungen
DE3787437T2 (de) Sialosylcholesterol, verfahren zu dessen herstellung und arzneimittel zur behandlung von krankheiten des nervensystems.
PH24094A (en) 5-aryl-3h-1,2,4-triazol-3-ones and their use as anticonvulsants
DE69220259D1 (de) Verfahren zur Herstellung von menschlichem NGF-2
ATE218372T1 (de) Antisense oligonnukleotide die mit der mrna cap aktivität interferieren und die translation inhibieren
DE60024969D1 (de) 2-methyl-3-butenyl-1-pyrophosphorsäuresalze und mittel zur behandlung von lymphozyten
DE69414375D1 (de) Verfahren zur herstellung von 1,1,1,2,2-pentafluoroethan, verfahren zur herstellung von 2,2-dichloro-1,1,1-trifluoroethan und verfahren zur reinigung von 1,1,1,2,2-pentafluoroethan
DE3886234D1 (de) DNA-Sequenzen, Plasmide und Mikroorganismen sowie Verfahren zur Herstellung von Chinolinsäure.
ATE232731T1 (de) Verwendung der gensequenz eines promotors zur behandlung rheumatischer erkrankungen
DE69433851D1 (de) Tiermodell zum testen von arzneistoffen zur behandlung von leukämie oder hiv

Legal Events

Date Code Title Description
8364 No opposition during term of opposition